Compare Novo Nordisk A/S (NVO) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs IAC/Interactivecorp — how do they compare? Novo Nordisk A/S trades at $45.07 (market cap $198.57B), while IAC/Interactivecorp trades at $37.76 (market cap $2.81B). The key difference: Novo Nordisk A/S is far larger — about 70.7× IAC/Interactivecorp's market cap, and Novo Nordisk A/S pays a 4.03% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals.
| NVO | PPLI | |
|---|---|---|
Market Cap | $198.57B | $2.81B |
Sector | Health | Media |
52-Week High | $63.98 | $47.62 |
52-Week Low | $35.29 | $31.52 |
Enterprise Value | $213.37B | $3.11B |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
PPLI trades at $38.38, down 1.56% today, with a bearish technical signal from moving averages. The company reported mixed quarterly results, including a significant Q2 2026 earnings beat of $6.77 per share versus expectations of a $0.40 loss, driven by gains from its MGM investment. Revenue has declined from $5.2B in 2022 to $2.4B in 2025, though 2026 projections show improved profitability with a 14.12% net margin. Recent news highlights participation in investor conferences and strategic focus on monetizing non-core assets.
The investment outlook is cautiously optimistic, supported by a 69% analyst buy rating and a $58.80 consensus price target implying 53% upside. Key opportunities include the undervalued MGM stake exceeding market cap and improving digital revenue. Risks involve declining revenue trends, negative operating cash flow in 2026, and a shareholder investigation announced in August 2026. The stock's low P/E of 6.49 and P/B of 0.56 suggest valuation appeal if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
